Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

ISTA files NDA with the FDA for Bepreve in allergic conjunctivitis ocular itching

Nov. 14, 2008

Recent Pfizer patent imparts new therapeutic agents for glaucoma

Nov. 7, 2008

Polyphor signs exclusive agreement with Allergan for PEM inhibitors in ophthalmology

Nov. 3, 2008

Santen patents novel HDAC inhibitors for glaucoma

Oct. 30, 2008

Lpath initiates dosing in phase I clinical trial of iSONEP in AMD

Oct. 21, 2008

Santen receives Japanese approval for Tapros in glaucoma and ocular hypertension

Oct. 20, 2008

Alcon signs licensing agreement with GSK for cilomilast and expands alliance with Origenis

Oct. 17, 2008

Sirion presents pivotal uveitis data for Durezol

Oct. 17, 2008

New therapeutic agents for eye disorders imparted in recent Santen patent

Oct. 17, 2008

Sirion launches Durezol for postoperative ocular inflammation and pain

Oct. 16, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...